Ken Griffin Pyxis Oncology, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$2.83 - $3.94 $1,698 - $2,364
600 Added 6.67%
9,600 $35,000
Q2 2024

Aug 14, 2024
SELL
$3.06 - $5.58 $7,038 - $12,834
-2,300 Reduced 20.35%
9,000 $29,000
Q1 2024

May 15, 2024
BUY
$2.03 - $6.59 $18,676 - $60,628
9,200 Added 438.1%
11,300 $48,000
Q4 2023

Feb 14, 2024
BUY
$1.4 - $2.09 $2,940 - $4,389
2,100 New
2,100 $3,000

Others Institutions Holding PYXS

# of Institutions
101
Shares Held
28.2M
Call Options Held
539K
Put Options Held
54.1K
View Full List

About Pyxis Oncology, Inc.

PYXS Quotes by TradingView
  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $69.8M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email